Health Care & Life Sciences » Biotechnology | Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
648.40
1,911.40
2,440.20
4,822.30
Cost of Goods Sold (COGS) incl. D&A
10.40
-
-
-
-
Gross Income
10.40
-
-
-
-
SG&A Expense
2,636.80
9,458.10
21,808.80
34,747.40
61,076
EBIT
2,647.20
8,853.70
19,985.10
32,562.80
56,747.70
Unusual Expense
124.00
-
-
-
191.20
Non Operating Income/Expense
4.60
2.00
14.10
41.90
284
Interest Expense
24.00
2.40
4.40
13.40
7.40
Pretax Income
2,540.50
8,850.70
19,998.70
32,421.60
55,672.10
Consolidated Net Income
2,540.50
8,850.70
19,998.70
32,421.60
55,672.10
Net Income
2,540.50
8,850.70
19,998.70
32,421.60
55,672.10
Net Income After Extraordinaries
2,540.50
8,850.70
19,998.70
32,421.60
55,672.10
Net Income Available to Common
2,540.50
8,850.70
19,998.70
32,421.60
55,672.10
EPS (Basic)
0.13
0.28
0.49
0.65
0.98
Basic Shares Outstanding
20,159.90
31,350.10
41,137.50
50,177.00
56,999.70
EPS (Diluted)
0.13
0.28
0.49
0.65
0.98
Diluted Shares Outstanding
20,159.90
31,350.10
41,137.50
50,177.00
56,999.70
EBITDA
2,636.80
8,809.80
19,897.40
32,307.20
56,253.80
Non-Operating Interest Income
2.10
3.40
4.90
196.50
990.20

About Corbus Pharmaceuticals Holdings

View Profile
Address
500 River Ridge Drive
Norwood Massachusetts 02062
United States
Employees -
Website http://www.corbuspharma.com
Updated 07/08/2019
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.